Literature DB >> 1374029

A simple procedure for tenascin purification.

M Saginati1, A Siri, E Balza, M Ponassi, L Zardi.   

Abstract

Here we describe a two-step procedure for purification of human tenascin from conditioned medium of the SK-MEL-28 human melanoma cell line. The first step consists in passing the conditioned media through two chromatography columns connected in sequence. The first is a large capacity gelatin--Sepharose affinity chromatography column (to remove fibronectin), the second, over which the unbound material from the first column flows directly, is a hydroxyapatite chromatography column. Under these conditions, all tenascin present in the conditioned medium binds to the hydroxyapatite chromatography column from which it is then eluted by a 5-300 mM sodium phosphate gradient. With this step, we obtain a crude tenascin preparation, concentrated about 20 times with respect to the starting conditioned medium, and in which tenascin represents more than 50% of the total protein. The second step consists of two sequential precipitations with 6% and 12.8% poly(ethylene glycol). After this step, tenascin is more than 95% pure and does not show any contamination of chondroitin-sulfate-containing proteoglycans that are known to bind to it. From 21 medium we obtain about 3-4 mg tenascin which corresponds to a yield of about 40-50%. This procedure gives a higher yield, is simpler with respect to procedures previously described, avoids the exposure of the protein to denaturing agents or harsh conditions and could be used for purification of tenascin from the conditioned media of other cell lines. Thus, this procedure may represent a simple and useful tool for the preparation of tenascin to study its biological functions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374029     DOI: 10.1111/j.1432-1033.1992.tb16811.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  3 in total

1.  Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

Authors:  R De Santis; A M Anastasi; V D'Alessio; A Pelliccia; C Albertoni; A Rosi; B Leoni; R Lindstedt; F Petronzelli; M Dani; A Verdoliva; A Ippolito; N Campanile; V Manfredi; A Esposito; G Cassani; M Chinol; G Paganelli; P Carminati
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

2.  The Promoting Effect of the Extracellular Matrix Peptide TNIIIA2 Derived from Tenascin-C in Colon Cancer Cell Infiltration.

Authors:  Hideo Suzuki; Manabu Sasada; Sadahiro Kamiya; Yuka Ito; Hikaru Watanabe; Yuko Okada; Kazuma Ishibashi; Takuya Iyoda; Akinori Yanaka; Fumio Fukai
Journal:  Int J Mol Sci       Date:  2017-01-17       Impact factor: 5.923

3.  Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment.

Authors:  G Klein; S Beck; C A Müller
Journal:  J Cell Biol       Date:  1993-11       Impact factor: 10.539

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.